Insider Selling: Insmed (NASDAQ:INSM) CFO Sells 1,678 Shares of Stock

Insmed, Inc. (NASDAQ:INSM) CFO Sara Bonstein sold 1,678 shares of the firm’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $175.07, for a total value of $293,767.46. Following the completion of the sale, the chief financial officer directly owned 81,953 shares of the company’s stock, valued at approximately $14,347,511.71. The trade was a 2.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Sara Bonstein also recently made the following trade(s):

• On Thursday, January 8th, Sara Bonstein sold 1,447 shares of Insmed stock. The stock was sold at an average price of $174.17, for a total value of $252,023.99.
• On Tuesday, January 6th, Sara Bonstein sold 1,517 shares of Insmed stock. The shares were sold at an average price of $173.33, for a total value of $262,941.61.

Insmed Stock Performance

Insmed stock traded down $5.73 during mid-day trading on Thursday, hitting $170.27. 2,588,589 shares of the company’s stock traded hands, compared to its average volume of 2,142,398. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.63 and a quick ratio of 4.34. The firm has a 50 day simple moving average of $190.79 and a two-hundred day simple moving average of $151.24. Insmed, Inc. has a fifty-two week low of $60.40 and a fifty-two week high of $212.75. The stock has a market cap of $36.31 billion, a price-to-earnings ratio of -27.51 and a beta of 1.08.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.40). The company had revenue of $142.34 million during the quarter, compared to the consensus estimate of $114.33 million. Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. Insmed’s revenue for the quarter was up 52.4% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.27) earnings per share. On average, research analysts expect that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insmed News Roundup

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: High-profile media attention — Jim Cramer singled out Insmed as “worth keeping an eye on,” which can attract retail interest and trading volume. Read More.
• Neutral Sentiment: Public SEC disclosures: the insider sales were reported in Form 4 filings (transparent regulatory reporting), and insiders still retain large positions — meaning these may be planned sales rather than full exits. See aggregated reporting of recent insider transactions. Read More.
• Negative Sentiment: Large, concentrated insider selling — multiple senior executives (CEO William Lewis, CFO Sara Bonstein, COO Roger Adsett and other insiders) sold thousands of shares across Jan. 6–8. Such clustered sales by top management often spook investors and can pressure the stock. One recent block sale by insider Orlov (87,290 shares, ~$15.3M) is particularly large and notable. Read More.
• Negative Sentiment: Investor litigation risk — Pomerantz LLP announced an investigation into claims on behalf of Insmed investors, which raises legal/settlement risk and typically weighs on sentiment until resolved. Read More.

Analyst Ratings Changes

A number of brokerages have recently issued reports on INSM. UBS Group reduced their price objective on Insmed from $223.00 to $215.00 and set a “buy” rating for the company in a report on Tuesday. Wells Fargo & Company set a $195.00 price target on Insmed in a research note on Thursday, December 18th. Jefferies Financial Group set a $269.00 price objective on Insmed in a research report on Wednesday, December 10th. Cowen set a $241.00 target price on Insmed in a report on Thursday, December 18th. Finally, Citigroup restated an “outperform” rating on shares of Insmed in a research note on Thursday, December 18th. Two research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Insmed currently has an average rating of “Moderate Buy” and an average price target of $205.64.

Institutional Trading of Insmed

A number of institutional investors have recently modified their holdings of the stock. Chung Wu Investment Group LLC acquired a new position in Insmed in the second quarter valued at about $173,000. Resolute Capital Asset Partners LLC acquired a new stake in Insmed during the second quarter worth about $2,748,000. Caxton Associates LLP bought a new position in Insmed in the 1st quarter valued at about $441,000. Assenagon Asset Management S.A. raised its position in shares of Insmed by 84.5% in the 2nd quarter. Assenagon Asset Management S.A. now owns 73,404 shares of the biopharmaceutical company’s stock valued at $7,387,000 after buying an additional 33,626 shares in the last quarter. Finally, Public Employees Retirement System of Ohio bought a new stake in shares of Insmed during the 2nd quarter worth approximately $5,578,000.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.